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these patients with poor long-term outcome may represent a significantly opportunity to
improve their prognosis.
Table. 
*Adjusted for age, sex, hospital characteristics.
1077-70 Implementation of Acute Myocardial Infarction 
Guidelines in Community Hospitals Without Cardiac 
Catheterization Labs: Are We There Yet?
David M. Larson, Scott W. Sharkey, Barbara T. Unger, Timothy D. Henry, Minneapolis 
Heart Institute Foundation, Minneapolis, MN, Ridgeview Medical Center, Waconia, MN
Background
In order to reduce delays to treatment for ST Elevation Myocardial Infarction (STEMI), the
National Heart Attack Alert Program, in 1993, recommended that emergency depart-
ments (ED) develop protocols for STEMI and monitor quality measures including time to
treatment intervals. The ACC/AHA guidelines on STEMI recommend specific protocols to
rapidly assess and treat STEMI patients. The goal of this study was to obtain information
regarding the current use of STEMI protocols, adherence to guidelines and quality
assessment practices in hospitals without catheterization labs in Minnesota.
Methods
In March 2003, we mailed surveys to ED medical directors or nurse managers in 111
Minnesota hospitals that did not have cardiac catheterization labs. In addition to hospital
size and distance to nearest cath lab, the survey asked the questions regarding proto-
cols, standing orders, quality assurance, decision making and indications for transfer of
pts with STEMI. 
Results
103 (93%) of hospitals surveyed responded (10 to 173 beds; mean 42) located from 12
to 300 miles (mean 74) from the nearest cardiac cath lab. Only 64% of hospitals had
STEMI protocol/guidelines and 45% had standing orders in the ED; 32% had neither. Of
those hospitals that had specific guidelines, only 6% addressed criteria for transfer to a
tertiary hospital. Decisions addressed in guidelines: indications and dose of thrombolyt-
ics (58%), indications and dose of beta blockers (48%), use of aspirin (62%), indications
and dose of heparin (54%), and low molecular weight heparin (23%). Only 50% of hospi-
tals have a formal Quality assessment process for STEMI. Door to drug intervals are
monitored in 53% of hospitals; use of aspirin in 46% and beta blockers in 35%.
Conclusion
Despite recommendations from the NHAAP and ACC/AHA to develop hospital specific
guidelines and protocols for STEMI, only two thirds of community hospitals in Minnesota
have these in place. These guidelines are incomplete and rarely address transfer criteria
to hospitals with PCI capability. Quality performance measurement was lacking in one
half of hospitals surveyed. Programs to help community hospitals develop and implement
guidelines should be encouraged.
1077-71 The Association Between Care and Outcomes in 
Patients With Acute Coronary Syndrome: National 
Results From CRUSADE
Eric D. Peterson, Matthew T. Roe, Barbara L. Lytle, L. Kristin Newby, Elizabeth S. Fraulo, 
W. Brian Gibler, E. Magnus Ohman, Duke Clinical Research Institute, Durham, NC, 
University of North Carolina at Chapel Hill, Chapel Hill, NC
Background: Demonstrating the association between adherence to ACC/AHA guide-
lines and better outcomes is an important step in motivating their adoption in clinical
practice. Methods: Using data from the CRUSADE Initiative, we studied 45,987 high-risk
ACS patients (ischemic ST changes and/or positive cardiac markers) treated at 403 US
hospitals between 4/00-4/03. We evaluated hospitals’ use of 9 ACC/AHA Class I care
indicators among eligible patients without contraindications. Hospitals were divided into
quartiles based on overall guidelines adherence, calculated as % of guidelines consistent
care out of total care opportunities. Results: There were significant performance gaps
for each of the 9 indicators between the leading and lagging hospital quartiles: from nar-
row (97 vs 88% for aspirin <24 hrs, p<0.0001) to wide (60 vs 28%, p<0.0001 for GP IIb-
IIIa inhibitors <24 hrs). Compared with lagging, leading centers tended to be larger
(mean bedsize 388 vs 321), more likely academic (34 vs 21%), and to have CABG/PCI
facilities (81 vs 59%, all p<0.001). The Figure displays average in-hospital mortality for
each hospital performance quartile after adjusting for patient and hospital features. Con-
clusion: Adherence to ACC/AHA Guidelines varies markedly among US hospitals. Hos-
pitals with the highest adherence have significantly better patient outcomes than those
less adherent. These data support the need for national ACS quality improvement efforts
designed to promote local change. 
1077-72 Assessment of Glycemic Control in Patients With 
Diabetes Mellitus Admitted With an Acute Coronary 
Syndrome
Darcy Green Conaway, David M. Safley, Philip G. Jones, Jonathan Enriquez, Michelle 
Stephan, John A. Spertus, Mid-America Heart Institute, Kansas City, MO, University of 
Missouri, Kansas City, MO
BACKGROUND:No diabetic patient should be treated for an acute coronary syndrome
(ACS) without also directing attention to their diabetes and its associated metabolic
abnormalities. To understand whether physicians are also attending to patients diabetes
at the time of their ACS, we describe the proportion of diabetic patients who have their
glycemic control assessed during an ACS hospitalization .
METHODS: 968 consecutive patients were prospectively determined to have an ACS.
Prospective chart review and retrospective analyses of laboratory data were performed
to determine whether ACS patients with known diabetes had a glycosylated hemoglobin
(HbA1c) assessed 90 days prior to or during their hospitalization. We also examined
whether patient characteristics or processes of care were associated with HbA1c assess-
ments.
RESULTS: Among diabetic ACS patients (n=235, 24%), HbA1c values were obtained in
163 (69%). Older patients were less likely than younger patients to have had an HbA1c
checked (60% of patients >/=70 vs. 67% for ages 60-69 vs. 79% for ages <60, p=0.02).
Of the 235 diabetic patients, 89 had an endocrinology consultation. Of the 59 patients
who received an endocrine consult without a prior HbA1c, 54 (92%) had one checked
after the consult. Of the 146 patients not receiving an endocrine consult, HbA1c values
were checked in 79 (54%, p<0.001 compared to those who had a consult). The admitting
blood sugars of patients without a consult or HgA1c were elevated (161±60 mg/dL; >200
mg/dL in 25% of patients).
CONCLUSIONS: Almost a third of known diabetics have no recent evaluation of their gly-
cemic control prior to or during an ACS admission. Older age and no endocrinology con-
sultation are associated with less frequent assessments of HbA1c. These data suggest
an important opportunity to improve diabetes care at the time of an ACS.
1077-73 Enhancing Quality of Heart Failure Care in Managed 
Medicare and Medicaid in North Carolina: Results of the 
North Carolina Achieving Cardiac Excellence (NC ACE) 
Project
David C. Goff, Jr., Mark W. Massing, Alain G. Bertoni, Jennifer Davis, Walter T. 
Ambrosius, Jill McArdle, Vanessa Duren-Winfield, Carla A. Sueta, Janet B. Croft, Wake 
Forest University Health Sciences, Winston-Salem, NC, Medical Review of North 
Carolina, Cary, NC
Background: Utilization of angiotensin converting enzyme inhibitors (ACE-I) and beta-
adrenergic receptor blockers (BB) in heart failure (HF) patients remain suboptimal
despite the results of clinical trials and evidence-based guidelines supporting their
use.This report provides the results of a collaborative quality improvement program for
HF care implemented in managed Medicare and Medicaid programs in North Carolina.
Methods: Managed care plans identified adult patients with HF during 2000 (pre-inter-
vention) and from November 1, 2001 through October 31, 2002 (post-intervention). A
stratified random sample of patients’ outpatient medical records were reviewed by trained
nurse abstractors to obtain data regarding type of heart failure, demographics, comorbid-
ities, and therapies. The intervention consisted of guideline summary dissemination, per-
formance audit with feedback, patient-specific chart reminders and patient activation
mailings.
Results: We sampled 1613 patients from 5 plans during the pre-intervention period and
1528 patients during the post-intervention period. Assessment of left ventricular function
increased from 81.7% to 85.3% of patients (p < 0.0001). Among patients with moderate
to severe left ventricular systolic dysfunction, there was no substantive change in treat-
ment with ACE inhibitors or vasodilators; whereas, appropriate treatment with beta block-
ers increased from 48.3% (with another 11.9% with documented contraindications) to
67.9% (with another 7.5% with documented contraindications). The quality gap
decreased from 39.8% to 24.6% (p < 0.0001).
Conclusion: Left ventricular function assessment improved despite high pre-intervention
rates. Treatment rates with ACE-I and vasodilators remained high, but did not improve.
Treatment rates with BB improved substantially translating into a significant public health
benefit. Given published data regarding benefits of BB, one might expect 50 fewer deaths
Diabetic 
Patients
Non-
Diabetic 
Patients
Adjusted Odds Ratio Diabetic/
Non-Diabetic (95% CI)*
Medications at within 6 
hrs of Admission, (%)
Aspirin 69 78 0.71 (0.61, 0.84)
Beta Blockers 25 33 0.77 (0.64, 0.92)
Medications at Discharge 
, (%)
Aspirin 80 86 0.67 (0.57, 0.79)
Beta Blockers 75 80 0.79 (0.66, 0.94)
ACE inhibitors 75 69 1.34 (1.05, 1.71)
Statins 56 63 0.86 (0.63, 1.18)
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in this population over 5 years as a result of this intervention. Health care payors should
consider development of financial incentives to encourage collaborative quality improve-
ment programs.
1077-74 Marked Underutilization and Geographic Variation in 
Secondary Prevention Pharmacologic Therapy in 
Patients With Chronic Angina Undergoing Treatment 
With Enhanced External Counterpulsation
Andrew D. Michaels, Sheryl Kelsey, Ozlem Soran, Elizabeth E. Kennard, University of 
California, San Francisco, San Francisco, CA, University of Pittsburgh, Pittsburgh, PA
Introduction: Despite the importance of antiplatelet agents, beta-blockers, angiotensin-
converting enzyme inhibitors (ACEIs), and hypolipidemic agents in patients with chronic
coronary artery disease (CAD), several studies have suggested that these agents are
substantially underutilized. Hypothesis: We sought to describe the contemporary use of
these pharmacologic agents among patients with chronic angina who were referred for
treatment with enhanced external counterpulsation (EECP). EECP is reserved for
patients with angina despite maximal medical therapy and revascularization. We sought
to test the hypothesis that there is geographic variation in the use of these therapies in
CAD patients. Methods: The International EECP Patient Registry (IEPR) enrolls consec-
utive patients undergoing EECP for chronic angina. We analyzed data on 4388 US
patients who underwent EECP for angina and were enrolled in the IEPR beginning in
January 1998. US Census definitions were used to categorize patients into 4 geographic
regions: Northeast (NE), West, South, and Midwest (MW). Results: This study included
1350 NE patients, 463 West patients, 1232 South patients, and 1343 MW patients.
Demographic and clinical characteristics, including age, sex, Caucasian race, prior MI,
diabetes, and hyperlipidemia, were similar among the 4 regions. Patients in the South
had the lowest incidence of prior coronary revascularization, multivessel disease, and
quality of life, while having the highest incidence of current smoking (9.5% in South vs
7.6% non-South). Patients in the MW had the highest mean angina class. South patients
had the lowest use of cardiac medication, including beta-blockers (55% in South vs 70%
non-South; p<.001) and aspirin (65% vs 74%; p<.001). There was no geographic varia-
tion in the use of calcium blockers (45% overall), ACEIs (38%), or lipid-lowering agents
(70%). Conclusions: There is substantial underutilization of antiplatelet agents, beta-
blockers, ACEIs, and hypolipidemic agents in US patients with chronic stable angina.
Variation across the country is striking, but all areas can improve the care of such
patients by increasing the appropriate use of these agents.
1077-75 Coronary Artery Bypass Grafting: Are We Getting With 
the Program?
Morley A. Herbert, Syma L. Prince, Mitchell J. Magee, Eric Eichhorn, Cardiopulmonary 
Research Science and Technology Institute, Dallas, TX, Medical City Dallas Hospital, 
Dallas, TX
Background: To minimize future cardiac events, American Heart Association guidelines
(1995, 2001) for treatment of patients with coronary artery disease recommended that
patients should be discharged on appropriate medications- beta-blocker, ACE inhibitor,
aspirin or other anti-platelet medication and cholesterol lowering medication when appro-
priate. This study examines discharge medicines prescribed patients after coronary
artery bypass grafting (CABG).
Methods: Data was exported from our STS certified database on 6914 patients undergo-
ing CABG between Jan 2000 and July 2003, and analyzed for the use of beta-blockers,
ACE inhibitors, aspirin (or other anti-platelet drug) and cholesterol lowering agent at dis-
charge.
Results: At discharge 10.3% of patients were prescribed all four classes of drugs, a fur-
ther 34.2% received 3 of the drugs, and 4.3% had no drugs prescribed (Table 1)
Of patients receiving only 1 drug at discharge, 86% were given aspirin or other antiplate-
let medication. When prescribed 2 drugs, 96.0% received aspirin, while beta-blockers
were prescribed to 56.9% and cholesterol lowering agents to 32.3% of the patients. In 3
drug regimens, aspirin was used in 99.1%, cholesterol lowering agents in 87.1% and
beta-blockers in 84.4% of the patients. Only 29.4% received a prescription for an ACE-
inhibitor.
Conclusions: Despite published medication guidelines, only 44.5% of patients being dis-
charged after CABG received prescriptions following the recommended drug regimen.
1077-76 Holiday Heart: Decreased Use of Evidence-Based 
Therapies in Patients With Acute Myocardial Infarction 
Admitted During Holiday Weeks
Trip J. Meine, Manesh R. Patel, Venita DePuy, Lesley Curtis, Sunil V. Rao, Kevin J. 
Schulman, James G. Jollis, Duke University Medical Center, Durham, NC, Duke Clinical 
Research Institute, Durham, NC
Background: Previous studies have found an increased mortality from myocardial infarc-
tion in December. We investigated the relationship between the use of evidence-based
therapies and admission during holiday weeks.
Methods: 134,609 patients in an observational Medicare database admitted with myo-
cardial infarction from 1994-1996 were studied. Patients admitted during the last 2 weeks
of December and the first week of January were compared with patients admitted all
other weeks. A model adjusting for patient, physician, hospital, and geographic charac-
teristics was used to determine a relationship between week of admission and the use of
proven therapies.
Results: Patients admitted during the holidays were less likely to receive aspirin, beta
blockers or reperfusion therapy, specifically primary coronary intervention (PCI) (Table 1).
Mortality in patients admitted during the holidays was also significantly higher at 30 days
and 1 year. After adjustment, patients admitted during the holidays remained less likely to
receive PCI (RR 0.9, p <0.01).
Conclusion: Patients admitted during holiday weeks are less likely to receive evidence-
based therapies, specifically primary coronary intervention.
POSTER SESSION
1096 Novel Approaches to Cardiovascular Care
Monday, March 08, 2004, Noon-2:00 p.m.
Morial Convention Center, Hall G
Presentation Hour: 1:00 p.m.-2:00 p.m.
1096-67 Balloon Mitral Valvuloplasty Performed in Mobile 
Catheterization Laboratory as Part of Community 
Outreach Program at Primary Care Hospitals
Praveen Chandra, Ravi Kasliwal, S. N. Misra, B. Rawat, R. B. Panwar, Ajay Kanojia, 
Naresh Trehan, Ashok Seth, Escorts Heart Institute and Research Centre, New Delhi, 
India, Norvic, Nepal
Several patients of pure severe mitral stenosis suffer due to lack of definitive treatment
options like balloon mitral valvuloplasty (BMV) in developing countries, due to prevailing
socioeconomic conditions. We present a new strategy of taking tertiary level care to peo-
ple’s doorsteps by performing BMV in Mobile Cardiac Catheterization Laboratory near a
peripheral primary care hospital as part of a Community Outreach Program. Method:
This multicentric study performed at 6 centres in India and Nepal was divided into 2
phases. Phase I included 150 patients and all procedures were done with a surgical
standby. After the success of Phase I, 210 patients were treated in phase II, without sur-
gical standby. Patients were assessed for suitability for BMV by transthoracic echocardio-
gram (TTE) & transesophageal echocardiogram (TEE) in phase I and only TTE in phase
II. Exclusion criteria were moderate to severe mitral regurgitation (MR), presence of left
atrial or appendage clots and a Wilkins’ echocardiographic score of > 8. Procedure was
done using Inoue Balloon technique with TTE guidance. Results are summarized in the
table 1. Age range was 8-80 yrs and 53% were females . Conclusion: BMV is feasible
and safe even if done in a mobile catheterization laboratory in a primary care hospital
setting and can be undertaken without any surgical standby. These results are of
immense significance especially in developing countries where lack of facilities preclude
treatment of many deserving patients of severe mitral stenosis.
% with 4 drugs % with 3 drugs
2000 5.9 29.3
2001 10.9 34.1
2002 15.0 37.7
2003 11.4 42.4
Females/Males 9.0/10.8 31.9/35.0
Caucasian 9.6 34.2
African-American 18.6 31.8
Hispanic 15.1 32.0
Other 17.3 38.9
On Pump/Off Pump 10.2/10.6 32.7/36.3
Table 1: Use of Evidence-Based Therapies and Outcomes in Patients with Acute 
Myocardial Infarction
Holiday
Weeks
Rest of Year p 
Aspirin Use (during admission) 77.2% 78.2% 0.02
Aspirin Use (at discharge) 69.0% 69.5% 0.4
Beta Blocker Use (during admission) 43.3% 44.8% 0.002
Beta Blocker Use (at discharge) 28.7% 30.6% <0.0001
Reperfusion Therapy 16.3% 17.4% 0.004
Primary Coronary Intervention 12.5% 15.3% <0.0001
30-Day Mortality 22.5% 20.5% <0.0001
1-Year Mortality 37.2% 34.9% <0.0001
